Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 1.00 |
| ▸ | FAP | Q12884 | 10/20 | 0.67 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.67 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.67 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Denagliptin SCHEMBL987759 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9DPP7 | |
| Denagliptin SCHEMBL682185 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9DPP7 | |
| Denagliptin SCHEMBL18815071 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9DPP7 | |
| Denagliptin SCHEMBL1035624 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9DPP7 | |
| Denagliptin SCHEMBL3151455 | 0.99 | DPP4 (0.98) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL13986697 | 0.94 | DPP4 (0.89) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL5549926 | 0.89 | DPP4 (0.80) | DPP4FAPDPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL3157260 | 0.88 | DPP4 (0.79) | DPP4FAPDPP8DPP9DPP7 | |
| Denagliptin SCHEMBL4801510 | 0.87 | DPP4 (0.76) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL12350113 | 0.87 | DPP4 (0.77) | DPP4FAPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150578-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | CADILA PHARMACEUTICALS LIMITED (IN) | 2013-06-13 | — | — | US | claimed |
| EP-2555617-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | Cadila Pharmaceuticals Limited (IN) | 2013-02-13 | — | — | EP | claimed |
| WO-2011125011-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | CADILA PHARMACEUTICALS LIMITED (IN) | 2011-10-13 | — | — | WO | claimed |
| US-9029567-B2 | Hypoglycemic compounds | CADILA PHARMACEUTICALS LIMITED (IN) | 2015-05-12 | — | — | US | disclosed |
| EP-2769978-A1 | saxagliptin derivatives | Cadila Pharmaceuticals Limited (IN) | 2014-08-27 | — | — | EP | disclosed |
| WO-2014074668-A1 | MODULATORS OF GPR119 AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20130150578-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | CADILA PHARMACEUTICALS LIMITED (IN) | 2013-06-13 | — | — | US | disclosed |
| EP-2555617-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | Cadila Pharmaceuticals Limited (IN) | 2013-02-13 | — | — | EP | disclosed |
| WO-2012145603-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012145604-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| WO-2011125011-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | CADILA PHARMACEUTICALS LIMITED (IN) | 2011-10-13 | — | — | WO | disclosed |
| EP-1654226-B1 | (2S,4S)-4-FLUORO-1- 4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL -2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2005009956-A1 | (2S,4S)-4-FLUORO-1-[4-FLUORO-BETA-(4-FLUOROPHENYL)-L-PHENYLALANYL]-2-PYRROLIDINECARBONITRILE P-TOLUENESULFONIC ACID SALT AND ANHYDROUS CRYSTALLINE FORMS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150578-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | GLP1R, GPR119, IAPP | DPP4 10/4885FAP 2786/4885DPP8 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.